The father of a Harvard College sophomore who killed himself in 2007 sued the school’s president and fellows for wrongful death, alleging the institution’s health service prescribed drugs known to increase suicide risk.
The huge missing “elephant in the room” is the high likelihood that Dr. Nidal Malik Hasan was medicated with potent brain-altering psychiatric drugs. These would be drugs that Dr. Hasan had easy access to and which he was probably prescribing widely to his psychologically traumatized soldier-patients, unaware of the serious dangers to them or to himself. These popular, aggressively marketed, highly profitable drugs are known to cause a number of serious adverse effects including hostility, suicidality, sleep alteration, depression, mania and psychotic episodes.
Death by suicide is at record levels in the armed services. Simultaneously the use of antidepressant drugs is also at record levels, including brand names like Prozac, Zoloft, Paxil, Celexa and Lexapro. According to the army, in 2007 17% of combat troops in Afghanistan were taking prescription antidepressants or sleeping pills. Inside sources have given me an even bleaker picture: During Vietnam, a mere 1% our troops were taking prescribed psychiatric drugs. By contrast, in the past year one-third of marines in combat zones were taking psychiatric drugs.
Data contained in the Army’s fifth Mental Health Advisory Team report indicate that, according to an anonymous survey of U.S. troops taken last fall, about 12% of combat troops in Iraq and 17% of those in Afghanistan are taking prescription antidepressants or sleeping pills to help them cope. Nearly 40% of Army suicide victims in 2006 and 2007 took psychotropic drugs — overwhelmingly, selective serotonin reuptake inhibitors (SSRIs) like Prozac and Zoloft.
A review of the scientific literature reveals that it is our drug-based paradigm of care that is fueling this epidemic. The drugs increase the likelihood that a person will become chronically ill, and induce new and more severe psychiatric symptoms in a significant percentage of patients.